Follow The Filings

LYEL Lyell Immunopharma Inc.

Health Care, filed as LYELL IMMUNOPHARMA INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.4%
  • $4.8M
  • 1 add

In 2026 Q2 James Silverman added to Lyell Immunopharma.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 0.44%

Who owns LYEL

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 0.44%, was 0.21% Add +334.9% 344,025 $4.8M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by LYEL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LYEL insider trades
  • $25M bought by 2 insiders
  • $74K sold by 1 insider outside a trading plan
  • $274 sold by 1 insider under 10b5-1 plans
  1. Innovative Cellular Therapeutics Holdings Ltd 10% owner
    Planned sale
    $137 10 shares at $13.70 <0.1% of stake
    Traded Jul 17 Filed Jul 20
    ↗
  2. Innovative Cellular Therapeutics Holdings Ltd 10% owner
    Planned sale
    $137 10 shares at $13.73 <0.1% of stake
    Traded Jul 16 Filed Jul 17
    ↗
  3. ARCH Venture Partners IX, LLC 10% owner, +4 joint filers
    Buy
    $12.5M 488,090 shares at $25.61 +52% to stake
    Traded Mar 6 Filed Mar 9
    ↗
  4. Veronica Sanchez Bulis VP, Corporate Controller
    Sale
    $74K 2,072 shares at $35.80 23% of stake
    Traded Dec 24–30 Filed Jan 6
    ↗

Also filed in the last 12 months, not counted as buying or selling: 25 sales to cover taxes, 4 stock grants, and 4 other transactions.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $130,000 $61,000 $36,000
Net income -$234.63M -$342.99M -$274.45M
Net margin * -180486.2% -562285.2% -762355.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $554.69M $379.59M $260.94M
Total non-current assets * $195.34M $111.26M $79.11M
Total assets $750.03M $490.86M $340.05M
Total current liabilities $34.52M $53.79M $49.41M
Total non-current liabilities * $60.56M $54.25M $42.44M
Total equity $654.95M $382.82M $248.2M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$163.69M -$162.39M -$150.02M
Cash from investing $184.05M $122.42M $54.1M
Cash from financing $1.74M $1.33M $50.41M
Net change in cash $22.1M -$38.64M -$45.52M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.